Cemiplimab: all 149 studies that test it
Page 2 of 2. Open to participants first (74), then studies with results posted, then the rest; newest registration first within each.
- Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT06219317Phase 2
- A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaActive, not recruitingNCT06190951Phase 2
- The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon CancerActive, not recruitingNCT05961709Phase 2
- Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before SurgerySuspendedNCT05929664Phase 2
- Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
- Deep sequencIng in Cutaneous Squamous CEll caRciNomasActive, not recruitingNCT05878288Phase 2
- Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung CancerWithdrawnNCT05840770Phase 2
- Cemiplimab/Peg-Interferon-α in Advanced CSCCWithdrawnNCT05729139Phase 1
- A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.Active, not recruitingNCT05704634Phase 1
- Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaActive, not recruitingNCT05694871Phase 2
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryActive, not recruitingNCT05608291Phase 3
- A Study of Radiation Therapy and Cemiplimab for People With Skin CancerActive, not recruitingNCT05574101Phase 2
- A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)Active, not recruitingNCT05557591Phase 2
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell LungActive, not recruitingNCT05553834Phase 2
- BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell LymphomaWithdrawnNCT05538988Phase 1/2
- Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaActive, not recruitingNCT05352672Phase 3
- A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With CemiplimabActive, not recruitingNCT05259709Phase 1
- THIO Sequenced With Cemiplimab in Advanced NSCLCActive, not recruitingNCT05208944Phase 2
- Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast CancerCompletedNCT05064085Phase 1
- Cemiplimab for Secondary AngiosarcomasCompletedNCT04873375Phase 2
- Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT04862650Phase 2
- Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT04831450Phase 2
- Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid MalignancyCompletedNCT04763616Phase 2
- SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIALTerminatedNCT04729725Phase 1
- LAG3 PET Imaging in Advanced Solid TumorsActive, not recruitingNCT04706715Phase 1/2
- Anti-PD1-antibody and Pulsed HHI for Advanced BCCActive, not recruitingNCT04679480Phase 2
- Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell CarcinomaActive, not recruitingNCT04632433Phase 2
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersActive, not recruitingNCT04626635Phase 1/2
- Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaActive, not recruitingNCT04543071Phase 2
- Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell CancerActive, not recruitingNCT04428671Phase 1
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
- Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin LymphomaWithdrawnNCT04373083Phase 2
- A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin CancerActive, not recruitingNCT04315701Phase 2
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsActive, not recruitingNCT04291105Phase 2
- Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral TherapyWithdrawnNCT04046107Phase 1/2
- Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT03969004Phase 3
- REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate CancerActive, not recruitingNCT03951831Phase 2
- Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsActive, not recruitingNCT03916627Phase 2
- Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell CarcinomaCompletedNCT03889912Phase 1
- Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsTerminatedNCT03684785Phase 1/2
- Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03580694Phase 1
- Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before SurgeryActive, not recruitingNCT03565783Phase 2
- Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced MalignanciesActive, not recruitingNCT03233139Phase 1
- An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)CompletedNCT03198130Phase 1
- Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced CancersCompletedNCT03005782Phase 1
- An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)CompletedNCT03002376Phase 1
- A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell MalignanciesCompletedNCT02651662Phase 1
- Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical StudyWithdrawnNCT02520245Phase 1
- Study of REGN2810 (Anti-PD-1) in Patients With Advanced MalignanciesCompletedNCT02383212Phase 1